We want to have a positive impact on the lives of people living with debilitating conditions and to change the narrative about cannabis for good.

Established in 2017, we are a biotech company harnessing the therapeutic power of cannabinoids. We are developing prescription medicines through a regulatory pathway, with a particular emphasis on targeting chronic pain. These are debilitating conditions where people may find themselves addicted to opioids, experiencing severe side effects or find their treatments don’t work anymore.  It is a market valued at nearly US$60bn and expected to rise to US$75bn by 2027.  Our aim is to develop non-addictive cannabinoid based medicines to meet this huge need.

Through our innovative portfolio we aim to leverage the power of our library of proprietary pharmaceutical cannabinoid derivatives to deliver medicines that will be first in class or have exclusivity in the market.